PCSK9 Inhibitors Added to Moderate/High-Intensity Statin Therapy Are Associated With Improved Liver-Related Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Leqvio (inclisiran) - Novartis

Praluent (alirocumab) - Sanofi, Regeneron

Repatha (evolocumab) - Amgen, Astellas

Ludovic Saba MD MSc 1; Michel Toutoungy MD 1; Wissam Ghusn MD 2; Lisa B.. VanWagner MD MSc 1

Aug 29, 2026